The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for AbbVie’s RINVOQ™( Upadacitinib), a once-daily selective and reversible JAK inhibitor, for the treatment of adult patients with moderate to severe...
Kaiser Permanente Research radio recently interviewed Dr. Michael A Bookman, an oncologist and investigator with Kaiser, discussing his participation in an international clinical trial sponsored by AbbVie, focusing on a PARP inhibitor called Veliparib to treat ovarian...
Biopharma developing cancer therapies are in demand as the growing industry vies for bigger and more valuable pipelines. Seattle-based, privately held Mavupharma was the latest to feel the demand with its acquisition by AbbVie, which seeks to bolster its early-stage...
AbbVie and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of...
AbbVie announced the U.S. FDA has lifted the partial clinical hold placed on CANOVA, a Phase 3 trial evaluating venetoclax (Venclexta or Venclyxto) for the treatment of relapsed/refractory multiple myeloma. The CANOVA trial is evaluating venetoclax in combination with...
Scientists at VCU Massey Cancer Center found that a novel combination of drugs is effective against acute myeloid leukemia (AML) in preclinical models. The findings, recently published in the Journal of Cancer Research, could lead to new and improved treatments for...